AD/PD 2021 | Evidence supporting the Aβ pathway in Alzheimer’s disease

Colin L. Masters, MD, Florey Institute of Neuroscience and Mental Health, Parkville, Australia, provides an overview of the evidence supporting a role for amyloid beta (Aβ) in Alzheimer’s disease (AD). Although Aβ might not be the only target for intervention in AD, the evidence is very compelling that Aβ is a major target. Prof. Masters points out that most of the evidence comes not only from observation of pathological specimens post-mortem but also from the genetic studies in the rare early-onset and late-onset of the disease that strongly implicate the Aβ pathway. This interview took place during the AD/PD™ 2021 conference.